Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
FASEB J. 2024 Nov 30;38(22):e70202. doi: 10.1096/fj.202402108R.
Dodecanedioic acid (DC12) is a dicarboxylic acid present in protective polymers of fruit and leaves. We explored the effects of DC12 on metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DC12 supplementation (100 mg/kg/day) was added to a high-fat diet (HFD) for 8 weeks in rodents to assess its impact on obesity and MASH prevention. Rats given DC12 experienced significant reductions of weight gain, liver and visceral fat weight, and improved glucose tolerance and insulin sensitivity. Liver histology showed protection against diet-induced MASH, with reduced steatosis, hepatocyte ballooning, and fibrosis. For weight-loss and MASH reversion, rats were fed HFD for 14 weeks, followed by 6 weeks with or without DC12. DC12 supplementation (100 mg/kg/day) led to a significant reduction of weight gain and liver weight. DC12 induced white adipose tissue beiging and reduced adiposity with a decrease of visceral fat. It also improved glucose tolerance, insulin sensitivity, and reduced hepatic gluconeogenic gene expression. Liver histology revealed a significant reduction in steatosis, hepatocyte ballooning, and inflammation as well as fibrosis, indicating MASH reversal. DC12 reduced hepatic lipogenesis enzymes as well as de novo lipogenesis measured by deuterated water and increased fatty acid β-oxidation. Plasma lipid profile showed lower triglycerides and phosphatidylcholines in the DC12 group. Notably, DC12 decreased mINDY expression, the cell membrane Na+-coupled citrate transporter, reducing citrate uptake and de-novo lipogenesis, linking its effects to improved lipid metabolism and reduced steatosis. We found that during the hepatic first pass, half of the DC12 ingested with water was taken up by the liver. The concentration of DC12 in the portal vein falls within the range identified in vitro as sufficient to inhibit citrate transport in hepatocytes.
十二烷二酸(DC12)是存在于水果和叶片保护聚合物中的一种二羧酸。我们研究了 DC12 对代谢相关脂肪性肝炎(MASH)和肥胖的影响。在啮齿动物中,将 DC12 补充剂(100mg/kg/天)添加到高脂肪饮食(HFD)中 8 周,以评估其对肥胖和 MASH 预防的影响。给予 DC12 的大鼠体重增加、肝和内脏脂肪重量显著减少,葡萄糖耐量和胰岛素敏感性得到改善。肝组织学显示对饮食诱导的 MASH 有保护作用,脂肪变性、肝细胞气球样变和纤维化减少。为了进行减肥和 MASH 逆转,大鼠先喂食 HFD 14 周,然后再喂食或不喂食 DC12 6 周。DC12 补充剂(100mg/kg/天)可显著减少体重增加和肝重。DC12 诱导白色脂肪组织米色化,减少内脏脂肪堆积,改善葡萄糖耐量、胰岛素敏感性,并减少肝糖异生基因表达。肝组织学显示脂肪变性、肝细胞气球样变和炎症以及纤维化明显减少,表明 MASH 逆转。DC12 降低了肝脂肪生成酶以及氘水测量的从头脂肪生成,并增加了脂肪酸β氧化。血浆脂质谱显示 DC12 组的甘油三酯和磷脂酰胆碱水平较低。值得注意的是,DC12 降低了 mINDY 表达,即细胞膜 Na+-偶联的柠檬酸转运体,减少了柠檬酸摄取和从头脂肪生成,将其作用与改善脂质代谢和减少脂肪变性联系起来。我们发现,在肝脏的第一次通过中,用水摄入的 DC12 有一半被肝脏吸收。门静脉中 DC12 的浓度落在体外确定的足以抑制肝细胞中柠檬酸转运的范围内。